trending Market Intelligence /marketintelligence/en/news-insights/trending/ub1rdtlgmavhadfngb5vtw2 content esgSubNav
In This List

Sun Pharmaceutical prostate cancer drug gets US FDA approval

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sun Pharmaceutical prostate cancer drug gets US FDA approval

India's Sun Pharmaceutical Industries Ltd. said the U.S. Food and Drug Administration approved its drug Yonsa to treat prostate cancer.

The approval covers use of Yonsa, or abiraterone acetate, in combination with methylprednisolone, to treat patients with metastatic castration-resistant prostate cancer. Pfizer Inc. markets methylprednisolone as Medrol.

Sun Pharmaceutical acquired Yonsa from Churchill Pharmaceuticals LLC, which is entitled to certain up-front and milestone payments, as well as royalties.

Johnson & Johnson unit Janssen Research & Development LLC sells abiraterone acetate under the name Zytiga.